CTOs on the Move

Synlogic

www.synlogictx.com

 
Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Synlogic raised $40M on 02/17/2016
Synlogic raised $30M on 04/16/2021

Similar Companies

Artizan Biosciences

Artizan Biosciences, Inc. is a biotechnology company with a mission to restore lives disrupted by inflammatory disease through innovation and advancement of microbiota-targeted therapies. We are leveraging our proprietary IgA-SEQ™ technology platform to distinguish disease-driving bacteria from the intestinal microbiota with the goal of developing new and potentially curative treatments.

BioTime

BioTime is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. BioTime`s pipeline is based on two platform technologies which encompass cell replacement and cell/drug delivery. BioTime`s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy in Phase 2 development for the treatment of dry age-related macular degeneration, the leading cause of blindness in the developed world. BioTime common stock is traded on the NYSE American and TASE under the symbol BTX.

Alder Biopharmaceuticals

Alder uses its proprietary technologies to uniquely identify, develop, produce and market its own antibody therapeutics. The work being done at Alder today will help those who suffer from cancer, autoimmune diseases, and inflammatory diseases.

Compass Therapeutics

Compass Therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. Compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. Novel scientific insights are validated and explored deeply inside our labs before Compass pursues the best proprietary combinations of therapeutics into human clinical trials.

Vanda Pharmaceuticals

Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.